EAACI Portal

Clinical characteristics of 140 patients infected by SARS‐CoV‐2 in Wuhan, China
A detailed clinical investigation of 140 hospitalized COVID‐19 cases suggest eosinopenia together with lymphopenia may be a potential indicator for diagnosis. Allergic diseases, asthma and COPD are not risk factors for SARS‐CoV‐2 infection. Elderly age, high number of comorbidities and more prominent laboratory abnormalities were associated with severe patients. The authors acknowledge all the healthcare professionals who helped and took care of the patients with COVID-19 for their great efforts and their selfless dedication in the medical operation against SARS-CoV-2. Read the full paper here.

The European Parliament Interest Group on Allergy and Asthma convened its first meeting of the 2019-2024 legislature on 20 November 2019, laying out the route to policy successes in Europe for allergy and asthma research, prevention and quality management. Hosted by Members of the European Parliament (MEPs) Sirpa Pietikäinen and Cristian-Silviu Bușoi, leading Interest Group members, the meeting explored policy improvements to address two of the most prevalent chronic diseases, which affect one in three Europeans and represent an ever-growing burden on societies and healthcare systems. Allergic diseases and asthma prevention as a priority for the incoming Commission: Wojciech Kalamarz (European Commission DG SANTE) highlighted that chronic diseases’ prevention will be a priority of the Von der Leyen Commission and called on Member States to increase investment in prevention, noting the cost-effectiveness of preventive measures. Taking action across sectors building on the “exposome” concept: Prof Ioana Agache (Past-President, European Academy of Allergy and Clinical Immunology (EAACI)) advocated for policies looking at the interconnections between human, animal and plant health, and food and water safety to improve prevention in the field of allergy and asthma, which are essentially multifactorial diseases stemming mainly from biological responses to a variety of environmental triggers and less from individual-genetic factors. Improving allergen labelling to better protect patients: Salvatore D’Acunto (European Commission DG GROW) noted the importance of fragrance allergens labelling for patients. He stated that the Commission is exploring different on- and off-product labelling options, and invited stakeholders to respond to the ongoing public consultation on fragrance labelling. Interconnecting the health, air quality and climate change agendas came across as a key message from representatives of the WHO European Centre for Environment and Health, the European Environmental Bureau and EAACI. The EU Green Deal has the potential to deliver important steps in this direction, by allowing a cross sectoral approach to air pollution, investment in sustainable agriculture and green financing – with the promise of considerable benefits to the health of future generations. Prof Stefano del Giacco (EAACI Vice-President Education and Speciality) underlined the importance of efficient city planning to reduce risks associated with exposures, as well as registries, machine-learning, and integrated surveillance networks to monitor air quality as tools to provide independent evidence and data support for science-based policy-making. MEP Karima Delli, Chair of the European Parliament TRAN committee, reaffirmed her commitment to reducing emissions from the transport sector, linked with many chronic diseases including allergy and asthma. A joint call for increased research funding and accelerated uptake of personalised medicine: Reflecting on MEP Dr Cristian-Silviu Bușoi’s perspectives, Dr Amalia-Irina Vlad (European Commission DG RTD) encouraged the allergy and asthma community to seize the opportunity of an enhanced Horizon Europe budget for research and innovation. Prof Vera Mahler (Paul-Ehrlich-Institut) noted that research should address the existing knowledge gap between biomarkers and clinical outcomes so that new treatments and products can be authorised. EAACI President Prof Marek Jutel highlighted the central role of implementing translational research and real world evidence to foster the integration of patient-oriented and population-based studies. Mikaela Odemyr, President of the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), called for universal patient access to personalised medicine which requires a reorientation of healthcare systems, with a focus on individual patients’ needs. “We need better national programmes and their implementation, early action to protect our biodiversity and improved urban environments to prevent allergies and asthma. We need European Allergy and Asthma reference centre, we need more efforts to improve urban air quality and indoor air quality, we need better information about chemicals in our daily environment and food ingredients. We need to enter a new era where no one suffers from allergy and asthma.” – MEP Sirpa Pietikäinen. Further insights from the event are available here.

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.

Read the full manuscript here.

Committed to inscreasing allergy awareness and driving policy changes for improved patient care. The EAACI White Paper tackles research-innovation-quality of care nexus for allergic diseases and asthma.

Read here the EAACI White Paper

The brand new Global Atlas of Skin Allergy is now available online in early release!!


Access it here.

Brand new content in the EAACI Media Library all OPEN ACCESS: We have now available on the Media Library all content from PAAM 2019